Follistatin-Like Protein 1 and Cardiovascular Diseases
https://doi.org/10.35401/2541-9897-2026-11-2-132-139
Abstract
This literature review highlights the importance of assessing follistatin-like protein 1 levels for diagnostic and prognostic purposes. It is anticipated that future scientific and clinical studies will confirm the feasibility as an adjunct laboratory tool for diagnosis and prognosis evaluation in patients with cardiovascular diseases. Modulation of the concentration and expression of follistatin-like protein 1 may represent a promising therapeutic approach in the management of cardiovascular pathology.
About the Authors
A. M. Alieva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Amina M. Alieva - Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy named after Academician G.I. Storozhakova.
1 Ostrovityanova St., Moscow, 117997
I. E. Baykova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Irina E. Baykova - Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy named after Academician G.I. Storozhakova.
Moscow
A. B. Sultangalieva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Albina B. Sultangalieva - 6th year Student.
Moscow
I. G. Nikitin
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Igor G. Nikitin - Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy named after Academician G.I. Storozhakova.
Moscow
References
1. Ahmadzadeh AM, Khodashahi R, Shabestari MM, et al. The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis. Curr Cardiol Rev. 2024;20(6):e180724231994. PMID: 39034719. PMCID: PMC11440331. https://doi.org/10.2174/011573403X304195240715103930
2. Alieva AM, Teplova NV, Batov MA, et al. Pentraxin-3 – a promising biological marker in heart failure: literature review. Consilium Medicum. 2022;24(1):53–59. (In Russ.). https://doi.org/ 10.26442/20751753.2022.1.201382
3. Alieva AM, Baykova IE, Reznik EV, et al. Heart-type fatty acid binding protein: the promising biological marker in heart failure. Russian Medical Inquiry. 2022;6(1):5–11 (In Russ.). https://doi.org/10.32364/2587-6821-2022-6-1-5-11
4. Horak M, Fairweather D, Kokkonen P, et al. Follistatinlike 1 and its paralogs in heart development and cardiovascular disease. Heart Fail Rev. 2022;27(6):2251-2265. PMID: 35867287. PMCID: PMC11140762. https://doi.org/10.1007/s10741-022-10262-6
5. Karisa P, Sylviana N, Fitria N, et al. FSTL-1 as a Novel Cardiokine of Cardiac Angiogenesis: A Systematic Review. Vasc Health Risk Manag. 2025;21:437-449. PMID: 40453420. PMCID: PMC12126109. https://doi.org/10.2147/VHRM.S509482
6. Bielka W, Przezak A, Pawlik A. Follistatin and follistatinlike 3 in metabolic disorders. Prostaglandins Other Lipid Mediat. 2023;169:106785. PMID: 37739334. https://doi.org/10.1016/j.prostaglandins.2023.106785
7. Gao Y, Ren J, Peng H, et al. Follistatin-like protein 1: Implications for renal disease progression. J Pharmacol Exp Ther. 2025;392(5):103564. PMID: 40239460. https://doi.org/10.1016/j.jpet.2025.103564
8. Mattiotti A, Prakash S, Barnett P, et al. Follistatinlike 1 in development and human diseases. Cell Mol Life Sci. 2018;75(13):2339-2354. PMID: 29594389. PMCID: PMC5986856. https://doi.org/10.1007/s00018-018-2805-0
9. Gu C, Xue H, Yang X, et al. Role of follistatin-like protein 1 in liver diseases. Exp Biol Med (Maywood). 2023;248(3):193200. PMID: 36533576. PMCID: PMC10107393. https://doi.org/10.1177/15353702221142604
10. Sylva M, Li VS, Buffing AA, et al. The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One. 2011;6(8):e22616. PMID: 21826198. PMCID: PMC3149603. https://doi.org/10.1371/journal.pone.0022616
11. Okabayashi K, Shoji H, Onuma Y, et al. cDNA cloning and distribution of the Xenopus follistatin-related protein. Biochem Biophys Res Commun. 1999;254(1):42-8. PMID: 9920730. https://doi.org/10.1006/bbrc.1998.9892
12. Pontemezzo E, Foglio E, Vernucci E, et al. miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1. Int J Mol Sci. 2021;22(9):4971. PMID: 34067060. PMCID: PMC8125323. https://doi.org/10.3390/ijms22094971
13. Alteköester AK, Harvey RP. Bioengineered FSTL1 Patches Restore Cardiac Function Following Myocardial Infarction. Trends Mol Med. 2015;21(12):731-733. PMID: 26596868. https://doi.org/10.1016/j.molmed.2015.10.006
14. Seki M, Powers JC, Maruyama S, et al. Acute and Chron ic Increases of Circulating FSTL1 Normalize Energy Substrate Metabolism in Pacing-Induced Heart Failure. Circ Heart Fail. 2018;11(1): e004486. PMID: 29317401. PMCID: PMC5765881. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004486
15. Prakash S, Borreguero LJJ, Sylva M, et al. Deletion of Fstl1 (Follistatin-Like 1) From the Endocardial/Endothelial Lineage Causes Mitral Valve Disease. Arterioscler Thromb Vasc Biol. 2017;37(9):e116-e130. PMID: 28705792. https://doi.org/10.1161/ATVBAHA.117.309089
16. Zhao Y, Sun J, Zhang W, et al. Follistatin-Like 1 Protects against Doxorubicin-Induced Cardiomyopathy through Upregulation of Nrf2. Oxid Med Cell Longev. 2020;2020: 3598715. PMID: 32831995. PMCID: PMC7421745. https://doi.org/10.1155/2020/3598715
17. Parfenova EV, Zubkova ES, Boldyreva MA, et al. Study of the influence of etoxidol on expression of follistatin-like protein-1 (FSTL-1) in myocardium after experimental infarction in rats. Biomed Khim. 2020;66(3):250-256. PMID: 32588831. https://doi.org/10.18097/PBMC20206603250
18. Li JP, He WB, Xu SW, et al. FSTL1 protects against acute aortic dissection by suppressing vascular smooth muscle cell phenotypic switching and degradation of the extracellular matrix. J Mol Cell Cardiol. 2025;198:60-73. PMID: 39631359. https://doi.org/10.1016/j.yjmcc.2024.11.008
19. Liu H, Li Y, Li M, et al. Follistatin-like 1 protects endo thelial function in the spontaneously hypertensive rat by inhibition of endoplasmic reticulum stress through AMPK-dependent mechanism. Clin Exp Hypertens. 2023;45(1):2277654. PMID: 37963199. https://doi.org/10.1080/10641963.2023.2277654
20. Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A. 2011;108(43):E899-906. PMID: 21987816. PMCID: PMC3203781. https://doi.org/10.1073/pnas.1108559108
21. Li KS, Jiang WP, Li QC, et al. MiR-29a in mesenchymal stem cells inhibits FSTL1 secretion and promotes cardiac myocyte apoptosis in hypoxia-reoxygenation injury. Cardiovasc Pathol. 2020;46:107180. PMID: 31945680. https://doi.org/10.1016/j.carpath.2019.107180
22. Xiao Y, Zhang Y, Chen Y, et al. Inhibition of MicroRNA9-5p Protects Against Cardiac Remodeling Following Myocardial Infarction in Mice. Hum Gene Ther. 2019;30(3):286-301. https://doi.org/10.1089/hum.2018.059. Epub 2018 Oct 31. Erratum in: Hum Gene Ther. 2023;34(13-14):664. https://doi.org/10.1089/ hum.2018.059.correx. Erratum in: J Med Food. 2024;27(2):210. PMID: 30101604. https://doi.org/10.1089/jmf.2022.0091.correx
23. Maruyama S, Nakamura K, Papanicolaou KN, et al. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med. 2016;8(8):949-66. PMID: 27234440. PMCID: PMC4967946. https://doi.org/10.15252/emmm.201506151
24. Peters MC, Di Martino S, Boelens T, et al. Follistatinlike 1 promotes proliferation of matured human hypoxic iPSCcardiomyocytes and is secreted by cardiac fibroblasts. Mol Ther Methods Clin Dev. 2022;25:3-16. PMID: 35317048. PMCID: PMC8917270. https://doi.org/10.1016/j.omtm.2022.02.005
25. Arrigoni R, Jirillo E, Caiati C. Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics. 2025;13(4):277. PMID: 40278593. PMCID: PMC12031459. https://doi.org/10.3390/toxics13040277
26. Lu Y, Yang J, Wu Q, et al. The Role and Molecular Pathways of SIRT6 in Senescence and Age-related Diseases. Adv Biol (Weinh). 2025;9(4):e2400469. PMID: 39913122. https://doi.org/10.1002/adbi.202400469
27. Xu H, Guo H, Tang Z, et al. Follistatin-like 1 protects against doxorubicin-induced cardiotoxicity by preventing mitochondrial dysfunction through the SIRT6/Nrf2 signaling pathway. Cell Biol Int. 2024;48(6):795-807. PMID: 38436106. https://doi.org/10.1002/cbin.12147
28. Lu L, Shao Y, Wang N, et al. Follistatin-like protein 1 attenuates doxorubicin-induced cardiomyopathy by inhibiting MsrB2mediated mitophagy. Mol Cell Biochem. 2024;479(7):1817-1831. PMID: 38696001. https://doi.org/10.1007/s11010-024-04955-9
29. Shen H, Cui G, Li Y, et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model. Stem Cell Res Ther. 2019;10(1):17. https://doi.org/10.1186/s13287-0181111-y. Erratum in: Stem Cell Res Ther. 2024;15(1):47. PMID: 30635025. PMCID: PMC6330478. https://doi.org/10.1186/s13287024-03662-y
30. Magadum A, Singh N, Kurian AA, et al. Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Mol Ther Nucleic Acids. 2018;13:133-143. PMID: 30290305. PMCID: PMC6171324. https://doi.org/10.1016/j.omtn.2018.08.021
31. Wang HB, Huang R, Yang K, et al. Identification of differentially expressed genes and preliminary validations in cardiac pathological remodeling induced by transverse aortic constriction. Int J Mol Med. 2019;44(4):1447-1461. PMID: 31364721. PMCID: PMC6713409. https://doi.org/10.3892/ijmm.2019.4291
32. Pahlavani HA. Exercise-induced signaling pathways to counteracting cardiac apoptotic processes. Front Cell Dev Biol. 2022;10:950927. PMID: 36036015. PMCID: PMC9403089. https://doi.org/10.3389/fcell.2022.950927
33. Xi Y, Hao M, Liang Q, et al. Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2ASMAD2/3 in rats following myocardial infarction. J Sport Health Sci. 2021;10(5):594-603. PMID: 33246164. PMCID: PMC8500809. https://doi.org/10.1016/j.jshs.2020.11.010
34. Hu S, Liu H, Hu Z, et al. Follistatin-like 1: A dual regulator that promotes cardiomyocyte proliferation and fibrosis. J Cell Physiol. 2020;235(9):5893-5902. PMID: 32017077. https://doi.org/10.1002/jcp.29588
35. Ponce-Ruíz N, Herrera-Moreno JF, Rojas-García AE, et al. Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population. Heart Vessels. 2024;39(6):563-570. PMID: 38381171. https://doi.org/10.1007/s00380-024-02364-y
36. Widera C, Giannitsis E, Kempf T, et al. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin Chem. 2012;58(8):1233-41. PMID: 22675198. PMCID: PMC3539794.https://doi.org/10.1373/clinchem.2012.182816
37. Tanaka K, Valero-Muñoz M, Wilson RM, et al. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci. 2016;1(4):207221. PMID: 27430031. PMCID: PMC4944656. https://doi.org/10.1016/j.jacbts.2016.04.002
38. Uematsu M, Nakamura K, Nakamura T, et al. Persistent Myocardial Production of Follistatin-like 1 Is Associated with Left Ventricular Adverse Remodeling in Patients with Myocardial Infarction: Myocardial production of FSTL1 in AMI patients. J Card Fail. 2020;26(8):733-738. PMID: 32470377. https://doi.org/10.1016/j.cardfail.2020.05.015
39. Aikawa T, Shimada K, Miyauchi K, et al. Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents. PLoS One. 2019;14(4):e0216297. PMID: 31034503. PMCID: PMC6488088. https://doi.org/10.1371/journal.pone.0216297
40. El-Armouche A, Ouchi N, Tanaka K, et al. Follistatinlike 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail. 2011;4(5):621-7. PMID: 21622850. PMCID: PMC3178753. https://doi.org/10.1161/CIRCHEARTFAILURE.110.960625
41. Lee SY, Kim DY, Kyung Kwak M, et al. High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state. Endocr J. 2019;66(3):241-251. PMID: 30745500. https://doi.org/10.1507/endocrj.EJ18-0352
Review
For citations:
Alieva A.M., Baykova I.E., Sultangalieva A.B., Nikitin I.G. Follistatin-Like Protein 1 and Cardiovascular Diseases. Innovative Medicine of Kuban. 2026;11(2):132-139. (In Russ.) https://doi.org/10.35401/2541-9897-2026-11-2-132-139
Views:
304
JATS XML
Email this article 
